HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dipyrone comedication in aspirin treated stroke patients impairs outcome.

AbstractBACKGROUND:
>50% of stroke patients rely on analgesic medication to control pain. Aspirin is the mainstay of medical treatment of stroke patients; however analgesic medication with dipyrone impairs aspirin antiplatelet effects ex-vivo. The clinical impact of this impairment is unknown. Therefore, we aimed to determine aspirin antiplatelet effects and neurological outcome in stroke patients with aspirin and dipyrone comedication.
METHODS:
We conducted a prospective cohort study in 41 patients with stroke. Primary outcome was pharmacodynamic response to aspirin in dipyrone treated stroke patients. Secondary outcome was neurological recovery after stroke. Pharmacodynamic response to aspirin was measured using arachidonic acid induced aggregation in light-transmission aggregometry. Neurological outcome was determined three months after stroke onset by telephone interview.
RESULTS:
Patient's characteristics were similar in the aspirin-alone group and the aspirin+dipyrone group. Impaired pharmacodynamic response to aspirin occurred in 62% (14/21) of patients with aspirin and dipyrone co-medication. Only 10% (2/20) of aspirin treated patients without analgesic comedication displayed residual platelet reactivity (P=0.001; odds ratio [OR], 18 [95% CI, 3.2-100]). Excellent neurological recovery (measured by three months follow-up modified Rankin Scale<2) was observed in 80% (16/20) of patients in the aspirin-alone group and 48% (10/21) of patients in the aspirin+dipyrone group (P=0.037; OR, 4.4 [95% CI, 1.1-17.7]).
CONCLUSIONS:
Dipyrone comedication in patients with stroke impairs pharmacodynamic response to aspirin. This is associated with worse clinical outcome. Therefore dipyrone should be used with caution in aspirin treated stroke patients.
CLINICAL TRIAL REGISTRATION:
https://clinicaltrials.gov/show/NCT02148939; Identifier: NCT02148939.
AuthorsLisa Dannenberg, Vladimir Erschoff, Florian Bönner, Michael Gliem, Sebastian Jander, Bodo Levkau, Malte Kelm, Thomas Hohlfeld, Tobias Zeus, Amin Polzin
JournalVascular pharmacology (Vascul Pharmacol) Vol. 87 Pg. 66-69 (12 2016) ISSN: 1879-3649 [Electronic] United States
PMID27301652 (Publication Type: Comparative Study, Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016 Elsevier Inc. All rights reserved.
Chemical References
  • Analgesics
  • Platelet Aggregation Inhibitors
  • Arachidonic Acid
  • Dipyrone
  • Aspirin
Topics
  • Aged
  • Aged, 80 and over
  • Analgesics (administration & dosage, pharmacology)
  • Arachidonic Acid (pharmacology)
  • Aspirin (administration & dosage, pharmacology)
  • Cohort Studies
  • Dipyrone (administration & dosage, pharmacology)
  • Drug Interactions
  • Female
  • Humans
  • Male
  • Middle Aged
  • Platelet Aggregation (drug effects)
  • Platelet Aggregation Inhibitors (administration & dosage, pharmacology)
  • Prospective Studies
  • Stroke (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: